On September 9, Inno Pharmaceutical announced that the company had completed the D round of financing of nearly 800 million yuan. This round of financing was led by Yuansheng Venture Capital and co-managed by Beijing State Administration, followed by institutions such as the Beijing Medical and Health Industry Investment Fund, Beijing Advanced Manufacturing and Intelligent Equipment Industry Investment Fund and its mutual fund managers Cornerstone Capital, Chengtong Science and Technology Innovation Fund, Junhe Investment, Gao Rong Investment, Northern Lights Venture Capital, and China Capital. The old shareholders made additional investments in joint capital and Chunjia Capital. The funds raised will mainly be used for international multi-center clinical trials of the company's core products in the pipeline.

On September 9, Inno Pharmaceutical announced that the company had completed the D round of financing of nearly 800 million yuan. This round of financing was led by Yuansheng Venture Capital and co-managed by Beijing State Administration, followed by institutions such as the Beijing Medical and Health Industry Investment Fund, Beijing Advanced Manufacturing and Intelligent Equipment Industry Investment Fund and its mutual fund managers Cornerstone Capital, Chengtong Science and Technology Innovation Fund, Junhe Investment, Gao Rong Investment, Northern Lights Venture Capital, and Zhongqi Capital. The old shareholders made additional investments in joint capital and Chunjia Capital. The funds raised will mainly be used for international multi-center clinical trials of the company's core products in the pipeline.